BioMarin, Pioneer in Phenylketonuria (PKU) and Gene Therapy, Receives FDA Fast Track Designation for PKU Investigational Gene Therapy, BMN 307

2nd Investigational Gene Therapy in Clinic, Potential 3rd Therapy in PKU Franchise, 15+ Year Commitment to PKU Community SAN RAFAEL, Calif., Oct. 2, 2020 -- (Healthcare Sales & Marketing Network) -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a pionee... Biopharmaceuticals, FDA BioMarin Pharmaceutical, phenylketonuria, gene therapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news